The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,251
Zhou, H., Wang, Y., Chen, J., He, A., Jin, J., Lu, Q., Zhao, Y., Li, J., Hou, M., Su, L., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05558-y · Cited by 2
Lim, S., Wellard, C. J., Moore, E., Harrison, S. J., Quach, H., Ho, P. J., Rajagopal, R., & Spencer, A. G. (2023) · Internal Medicine Journal · doi:10.1111/imj.16277 · Cited by 2
Miyahira, A. K., Kamran, S. C., Jamaspishvili, T., Marshall, C. H., Maxwell, K. N., Parolia, A., Zorko, N. A., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24721 · Cited by 2
“128 The immune system does not work with its individual components in isolation, rather it functions as a whole with each component affecting the others in numerous ways we are still elucidating.”
BackgroundRecurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab
Hurtado, A., Luebbe, S. T., Kilbane, E. G., et al. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102763 · Cited by 2
Kashyap Patel, M. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.88856 · Cited by 2
Jurgens, E. M., Mitra, S., Herrera, K., Nemirovsky, D., Bready, B., Derkach, A., Hosszu, K., McAvoy, D. P., Firestone, R., Rajeeve, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.28.25338924 · Cited by 2
Self-citationMaura, F., Freeman, C. L. L., Maclachlan, K. H., Larráyoz, M., Ziccheddu, B., Meermeier, E. W., Garcés, J., Durante, M. A., Lee, H., Firestone, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.08.692978 · Cited by 2
Self-citationSlade, M., Fiala, M. A., Kirchmeyer, M., King, J., Gao, F., Schroeder, M. A., Stewart, A. K., Stockerl-Goldstein, K. E., Chen, C. I., & Vij, R. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.014 · Cited by 1
Shrinking the divide: improving myeloma CART access
Nooka, A. K., Hartley-Brown, M. A., Anderson, K. C., & Lonial, S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011659 · Cited by 1
“8,9 There is at present no reliable comparative data that evaluates innate immunity, cytokine, and myeloma responses between NHB and NHW patients with MM.”
BackgroundSelf-citationCosta, L. J., & Rodríguez‐Otero, P. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02842-9 · Cited by 1
Shah, M., Chaer, F. E., Ho, D. Y., & Boghdadly, Z. E. (2024) · Transplant Infectious Disease · doi:10.1111/tid.14283 · Cited by 2
Barberio, J., Lash, T. L., Nooka, A. K., Naimi, A. I., Patzer, R. E., & Kim, C. (2024) · Acta Haematologica · doi:10.1159/000539127 · Cited by 1
Self-citationImmunotherapy in multiple myeloma
Cantó, P. A., Arnao-Herráiz, M., & Comos, J. D. L. R. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.05.003 · Cited by 1
Yashar, D., Regidor, B. S. S., Goldwater, M., Bujarski, S. E., Dosso, A. D., & Berenson, J. R. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241275797 · Cited by 2
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
Durand, R., Bellanger, C., Descamps, G., Dousset, C., Maïga, S., Derrien, J., Thirouard, L., Bouard, L., Asnagli, H., Beer, P. A., et al. (2024) · HemaSphere · doi:10.1002/hem3.70016 · Cited by 1
Self-citationRichardson, T., Kobbe, G., Fenk, R. R., Schroeder, T., Crysandt, M. M., Neuerburg, C., Holderried, T. A. W., Schütte, D., Gödel, P., Hallek, M. J., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14346 · Cited by 1
Ho, P. J., & Li, E. W. (2025) · Internal Medicine Journal · doi:10.1111/imj.16647 · Cited by 2
“26 Overall, CRS occurred in 58% – 72%, mostly mild, with step-up dosing as mitigation; prophylactic tocilizumab has been shown to reduce the incidence and severity of CRS. 22,23,26,28 Management is similar to CAR-Ts which include tocilizumab, steroids and supportive care as the key elements.”
InfluentialHueso, T., Cagnat, J., Ouali, K., Haberstich, M., Henry, B., Danu, A., Bigenwald, C., Merad-Boudia, M., Messayke, S., Laparra, A., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf164 · Cited by 1
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
Pelland, A.-A., Dumas, M., Lemieux‐Blanchard, É., LeBlanc, R., Côté, J. A., Boudreault, J., Duquette, D., Kaedbey, R., Lalancette, M., Larose, F., et al. (2025) · Current Oncology · doi:10.3390/curroncol32040238 · Cited by 1
“The MajesTEC-1 prophylactic tocilizumab cohort showed a reduced rate of CRS following teclistamab administration of 25% compared to 72% in the non-prophylaxis cohort, and all events were noted to be of grade 1 or 2 [13].”
InfluentialAriane, B., Harel, S., Bertrand, A., et al. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.04.008 · Cited by 1
New therapeutic options and trends in the treatment of multiple myelom
Hájek, R., Muroňová, L., Mihályová, J., Horňáková, M., Popková, T., Plonková, H., & Jelı́nek, T. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.031 · Cited by 1
Cardiovascular complications of cellular immunotherapies and associated risk factors
Grunblatt, E., & Akhter, N. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00057-7 · Cited by 1
“MostofthedataregardingCVAEsfollowingBiTEtherapycomesfrom the original clinical trials of these therapies, which reported isolated incidents of cardiac arrest and heart failure for blinatumomab and a low incidence of arrhythmias for teclistamab and epcoritamab, respectively 52,54,55 .”
Lin, M., Xie, Y., Wu, J., Zhang, C., Shi, S., Lin, N., Tong, X., & Li, Y. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70228 · Cited by 3
“Although rare, fatal cases of hepatic failure and instances of immune-mediated DILI have been documented [72].”
Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma
Rios‐Olais, F. A., & Hilal, T. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016176 · Cited by 1
Llinares, J., Toribio-Castelló, S., García, L. F., Iglesias, T., Heredero, A., Rebollo, P., Ricote, I., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.07.008 · Cited by 1
Self-citationGarcia, R. G., Abonour, R., & Suvannasankha, A. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251364807 · Cited by 1
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
“The time to response is rapid for all TCEs around 1–2 months [56,64,65].”
InfluentialDean, E. A., Yang, L.-J., Seifert, R. P., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630929 · Cited by 1
Ntanasis‐Stathopoulos, I., Katsadouros, I., Malandrakis, P., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15220 · Cited by 1
T cell redirecting therapy for relapsed multiple myeloma
Tan, M. S. Y., Hellou, T., & Dingli, D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03432-z · Cited by 1
Zweegman, S., Smits, F., & van de Donk, N. W. C. J. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0292 · Cited by 1
Self-citationCAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 1
Jenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2
Soekojo, C. Y., Chung, S. J., Tsai, M.-T., Chen, W.-M., Huang, J., Kim, J. S., Lee, D., Min, C., Suzuki, K., Swaminathan, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.005 · Cited by 1
Tan, P. T., Bao, L., Yin, Q., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70115 · Cited by 1
“In heavily pretreated patients with RRMM, BCMA-targeted CAR-T and bispecific TCEs therapies [2, 3] have demonstrated objective response rates (ORR) ranging from 61% to 97%.”
The importance and utility of post market drug safety monitoring in cancer therapy
Levêque, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2575099 · Cited by 1
“In addition, 11,5% (19/165) of patients died of adverse events including 12 from Covid-19, after a median follow-up of 14.1 months [90].”
InfluentialKamboj, I., Habib, A., Chang, D., Rashid, A., Vegel, A. J., Graf, K., Struble, E., Mushtaq, M., Mahmoudjafari, Z., Green, K., et al. (2025) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2025.09.015 · Cited by 2
Identification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 1
Kitamura, A., Fujita, S., Isono, Y., Nakano, T., Morino, T., Tozuka, K., Kudo, H., Abe, R., Kohashi, S., & Toyama, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102851 · Cited by 1
Kidney toxicities of modern cancer immunotherapies: Mechanisms, diagnosis, and management
Arriola‐Montenegro, J., Mohan, A., & Herrmann, S. M. (2025) · Journal of Onco-Nephrology · doi:10.1177/23993693251390613 · Cited by 1
“By directly linking T cells to their targets, BiTEs bypass the need for conventional antigen presentation and deliver a potent, continuous immune response 58 (Figure 3).”
InfluentialmRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma
Feng, Y., Du, Y., Zhang, C.-T., Xie, F., & Yan, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189493 · Cited by 2
Sontayananon, N., Yuti, P., Sawasdee, N., Okada, S., Junking, M., Sujjitjoon, J., & Yenchitsomanus, P.-T. (2025) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2025.118820 · Cited by 1
Suzuki, T., & Iida, S. (2025) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.25038 · Cited by 2
“17,18 Consequently, long-term monitoring is required.”
InfluentialPasvolsky, O., Marcoux, C., Milton, D. R., Haider, A. A., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Smallbone, P., Lin, P., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02771-3 · Cited by 2
Gnann, D. C., Steinke, S., Garritsen, H. S. P., & Hust, M. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7343647 · Cited by 1
“Anti-CD38 therapeutic antibodies have been fundamental in advancing the treatment of multiple myeloma [17, 18], while gaining relevance through an increasing number of off-label uses and clinical trials for the treatment of further plasma cell disorders and hematologic malignancies [19 – 22] as…”
Piron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 3
Self-citationQureshi, Z. A., Jamil, A. R., Samsuddoha, K., & Kahlon, N. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001295 · Cited by 1
Dean, E. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1705345 · Cited by 5
“Neutropenia (any grade, Grade ≥ 3) was recorded in 70.9%, 64.2% in cases; infections (any grade, Grade ≥ 3) in 76.4%, 44.8% (14).”
InfluentialTrends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection
Pickl, J. F., & Oberbauer, R. W. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag011 · Cited by 1
Oliver, G. R., Barnett, C. C., Hightower, K. E., Kang, Y., & Baljević, M. (2026) · Cancers · doi:10.3390/cancers18030411 · Cited by 1
Mersi, J., Burow, L., Zhou, X., Eisele, F., Fante, M., Riedhammer, C., Stich, A., Isberner, N., Afrin, N., Duell, J., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017889
Gullà, A., Dhodapkar, M. V., Einsele, H., Raab, M. S., Solimando, A. G., Botta, C., Turi, M., Sester, L. S., Portuguese, A. J., Steinbrunn, T., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0107 · Cited by 1
Guo, Y.-L., Ma, L.-X., Yang, F., Fu, Z., Li, D.-Y., Liu, R., Cao, M., Wei, B., Dou, Y., Deng, B., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1756209 · Cited by 1
“Notably, grade 4 myelosuppression incidence was signi fi cantly higher than prior reports in BCMA-CAR-T RRMM. (31, 32).”
First-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 1
Self-citationHashim, M. M. A., Ahsan, M., Khan, M. A. M., Hafsa, T. H., Khan, T. K., Zahoor, K., Muzaffar, S., Fatima, F., Zahra, S. T., Naeem, A., et al. (2025) · Oncoscience · doi:10.18632/oncoscience.643 · Cited by 2
“Bispecific antibodies, particularly CD3-directed T-cell engagers such as teclistamab, epcoritamab, and blinatumomab, represent an emerging class of non– checkpoint immunotherapies with expanding use across hematologic and select solid malignancies [31].”
Li, J., Lu, Q., Zhu, Z., Wang, X., Chen, Y., Zhang, Z., Yu, Z., Wang, Z., Chen, Y., Xie, H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013986 · Cited by 1
“HeLa cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS and 100 U/mL penicillin-streptomycin.”
Hameed, M., Habib, A., Khan, A., et al. (2026) · Cancers · doi:10.3390/cancers18050740 · Cited by 1
“Additionally, infections occurred in 76.4% of patients, with grade 3/4 infections in 44.8% [5].”
InfluentialSwain, R. N., Wadhera, S., Jandial, A., Singh, C., Jain, A., Prakash, G., Khadwal, A., & Malhotra, P. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.02.010 · Cited by 1
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma
Corona, M., García-Vicente, R., Sáez, A., Ancos-Pintado, R., Rodríguez-García, A., Arroyo, A., Sánchez, A. B., Chari, A., Martin, T., Wolf, J. L., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014224 · Cited by 1
Self-citationMiyashita, A., Kondo, S., Takaoka, K., Nishimura, Y., & Rodgers, T. D. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.002 · Cited by 1
Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
Ssentongo, P., Guare, E. G., Song, C., Inoue, Y., Sandhu, M., Annageldiyev, C., Sivik, J. M., Rakszawski, K. L., Naik, S. G., Minagawa, K., et al. (2026) · Current Oncology · doi:10.3390/curroncol33030154 · Cited by 1
“The median age in our cohort was 72 years (compared to 64 in the trial population and 67–68 in real-world studies) with 3 patients ≥ 75 years [2,4,10,11].”
InfluentialCognitive dysfunction associated with cellular immunotherapy for cancer
Hauswirth, A. G., Parsons, M. W., & Dietrich, J. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag021 · Cited by 1
Ntanasis‐Stathopoulos, I., Manganas, S., Filippatos, C., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70312 · Cited by 1
“Ultimately, 7 records met the inclusion criteria, annunciating results from 3 pivotal clinical trials [22–25] and 4 clinical studies [26–31].”
InfluentialFerreri, C. J., Atrash, S., Knight, M., Davis, D., McKay, J., Lambird, J. E., Homsy, S., Bernal‐Mizrachi, L., Friend, R. N., Paul, B. A., et al. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100050 · Cited by 1
Ocio, E. M., Parmar, G., Mateos, M., Leleu, X. P., Buck, T. T., Tan, C. R., Curry, N. C., Ling, S., Quach, H., Mai, E. K., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2659263 · Cited by 2
Self-citationLuo, Q., Zhang, X., Qiu, X., et al. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s588402 · Cited by 1
Shibata, K., Tsutsumi, K., Murakami, H., Mizuta, E., 池田, 峻., Kogue, Y., Kano, M., Sanda, K., Maehara, Y., Akamine, H., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02969-4 · Cited by 1
Saxena, A., Yorker, M., Zorko, N. A., Narayan, V., Siddiqui, B. A., Saraiya, B., Tester, W. J., Mille, P. J., Shaver, A. L., Nikita, N., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag172 · Cited by 1
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations
Ahn, M., Szabados, B. E., Ince, W., Kim, J., Ku, B. M., & Keenan, B. P. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517508 · Cited by 1
Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imager
Davis, B., & Masri, A. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102727 · Cited by 1
Li, J.-S., Abulaiti, A., Li, D.-Y., Zhao, Y., Wahafu, P., Maimaitiming, M., Qiu, S., Zhang, Y.-X., An, Y.-Q., Wang, W.-X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1811816 · Cited by 1
Torpe, A. H., Thorsen, J., Mathiasen, G., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70383 · Cited by 1
Dermatologic Adverse Events Associated with T-Cell Engager Therapy
Patil, M. K., Wang, B., LeBoeuf, N. R., Nambudiri, V. E., & Shi, C. R. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01041-2 · Cited by 1
“All events were grade 1 or 2, and no other dAEs were reported [46].”
Five trials reshaping multiple myeloma
Talbot, A., Bobin, A., Touzeau, C., et al. (2026) · Med · doi:10.1016/j.medj.2026.101177 · Cited by 1
Huang, S., Luo, J., Yu, G., et al. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108267 · Cited by 1
Harzer, M., Gross-Fengels, N.-O., Melzer, F., Molwitz, I., Kosch, R., Al-Bazaz, M., Artzenroth, J., Cords, L., Bartke, L., Kamili, A., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07118-6 · Cited by 1
Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K. C., Straßl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07140-8 · Cited by 2
Longobardi, S. A., Oo, S. L., Saini, M., et al. (2026) · Cureus · doi:10.7759/cureus.111115 · Cited by 1
Hej-Ali, S., Banwell, K., Mohamed, H., Cervi, A., Dass, A., Gupta, R., Hamm, C. M., Kanjeekal, S. M., Strange, I. S., Szalay, M., et al. (2026) · Cancers · doi:10.3390/cancers18132083 · Cited by 1
“In a 165-patient, phase I/II teclistamab study (MajesTEC-1), 76.4% of patients experienced infection AEs of any grade [31].”
InfluentialKim, H. I., Lee, D., & Huh, J.-Y. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0055 · Cited by 1
Scheid, C., Gödel, P., Krone, C., Carpinteiro, E., Hallek, M., Holtick, U., & Richardson, T. (2026) · HemaSphere · doi:10.1002/hem3.70417 · Cited by 1
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia
Gaballa, M., Julian, K. L., Afrough, A., Hansen, D. K., Goel, U., Corraes, A. D. M. S., Dima, D., Rana, M. S., Hosoya, H., Mikkilineni, L., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020826 · Cited by 2
Self-citationSystemic light chain and transthyretin amyloidosis—treatment advancements and future directions
Bianchi, G., Sanchorawala, V., Wechalekar, A. D., Grogan, M. A., Cuddy, S. A. M., & Merlini, G. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00302-8 · Cited by 1
Richter, J. R., Lee, H. C., Jagannath, S., Zonder, J. A., Hoffman, J. E., Zhou, Z., García-Horton, V., Fillbrunn, M. K., Wang, H., Mattera, M., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2688561 · Cited by 1
“Other bsAbs, including elranatamab, talquetamab, and teclistamab, are also approved for TCE RRMM [9–11] but no direct head-to-head comparisons between bsAbs are available.”
Mondal, S., Becker, N. J., Huo, Y., Zhang, P., Johnson, T. S., Landgren, O., Coffey, D. G., Walker, B. A., & Liu, E. (2026) · Biomedicines · doi:10.3390/biomedicines14071556 · Cited by 2
“%) in BCMA therapies [25,101,185], for which expression can be found in the colon and intestine (Figure 3), as well as skin-related (67%), nail-related (57%~65%), rash-related (18%~47%), dysgeusia (53%~67”
Manzato, E., Puppi, M., Barbato, S., Vitale, D. A., Sacchetti, I., Masci, S., Restuccia, R., Ghibellini, S., Pantani, L., Mancuso, K., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020762 · Cited by 1
“Of note, CRS incidence was similar among inpatient and outpatient SUDs (69% vs 67%), though outpatients showed a trend for later onset (2 [1-10] vs 5 [2-9] days; P = .071).”
Leitner, T., Oelschläger, L., Mosquera, F. H., Schaefers, C., Leypoldt, L. B., Weisel, K. C., von Bubnoff, N., Rückert, M., Kimmich, C., Ahmed, H., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2699285 · Cited by 1
Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy
Gadoth, A., Paran, Y., Mina, Y., Levy, O., Shragai, T., Cohen, Y. C., Weigert, N., Barchad, O. W., Friedman, Y., Magen, H., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200633 · Cited by 1
Functional Characteristics Derived from the Structural Design of Bispecific Antibodies
Han, J., Lim, S. Y., Kim, Y., Jeong, D.-H., Kim, H., Ha, S., Park, J., Won, Y., & Lim, K. S. (2026) · Pharmaceuticals · doi:10.3390/ph19081245 · Cited by 1
“In these 1 + 1 formats, productive immune synapse formation depends on BCMA availability, the intrinsic affinity and kinetics of each arm, epitope geometry, and systemic exposure [88–90].”
InfluentialLeonard, J., Duhamel, M., & Salzet, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02902-2 · Cited by 2
“Now, bispeci fi cs are being developed for various targets: e.g., CD3 × BCMA (teclistamab, for myeloma 211 ), or CD3 × EGFR (in trials for solid tumors).”
Mandal, S., Maji, M., & Dhali, A. (2026) · Cancer Medicine · doi:10.1002/cam4.72241 · Cited by 1
He, X., Chen, G., Zhan, Z., & Li, Z. (2026) · Hematology · doi:10.1080/16078454.2026.2730041 · Cited by 1
Phase 1 Study of Anito-cel, a d -Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Frigault, M. J., Dhakal, B., Jakubowiak, A. J., Raje, N. S., Banerjee, K., Mu, C. J., Hart, K. C., Shachar, S., Andrews, L. P., Cheung, L. S., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603527 · Cited by 1
Madan, S., Costello, C. L., Lipe, B. C., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00228-0 · Cited by 1
Self-citationMaroun, J. A. (2011) · Current Oncology · doi:10.3747/co.v18i0.957 · Cited by 1
Mohyuddin, G. R., Kapur, R., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18755 · Cited by 1
Management of Relapsed/Refractory Multiple Myeloma
Callander, N. S. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.5003 · Cited by 1
“3 months.(9) Cytokine-release syndrome can oc-”
Case 29-2023: A 34-Year-Old Woman with Abdominal Distention and Acute Kidney Injury
Jagannath, S., Anderson, M., Yee, A. J., & Hasserjian, R. P. (2023) · New England Journal of Medicine · doi:10.1056/nejmcpc2027091 · Cited by 1
A Year of Advances in Precision Therapy for Blood Cancers
The AACR Cancer Progress Report 2023 Steering Committee (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0193 · Cited by 1
Suzuki, K., & Yano, S. (2023) · Life · doi:10.3390/life13112229 · Cited by 1
“Currently, the detection of new drugs for suitable targets, such as B-cell mature antigen (BCMA) [103–105], G protein-coupled receptor class C group 5D (GPRC5D) [106,107], and Fc receptor-homolog 5 (FcRH5) [108], is developing.”
Background
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
